NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) Conference

Lassman, Andrew, Polly, Mei-Yin, Iwamoto, Fabio et al. (2023). NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) . NEURO-ONCOLOGY, 25

cited authors

  • Lassman, Andrew; Polly, Mei-Yin; Iwamoto, Fabio; Sloan, Andrew; Wang, Tony; Aldape, Kenneth; Wefel, Jeffrey; Gondi, Vinai; Gutierrez, Alonson; Manasawala, Mohammed; Gilbert, Mark; Sulman, Erik; Wolchok, Jedd; Green, Richard; Neil, Elizabeth; Lukas, Rimas; Goldlust, Samuel; Snuderl, Matija; Dignam, James; Won, Minhee; Movsas, Benjamin; Mehta, Minesh

authors

date/time interval

  • November 15, 2023 -

publication date

  • November 1, 2023

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • CANADA, Vancouver

Conference

  • 28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO)

publisher

  • OXFORD UNIV PRESS INC

volume

  • 25